undamentalytics Newsletter
Sign in

Inhibrx Biosciences, Inc. revenue

Inhibrx Biosciences, Inc.'s revenue was $1.3m in fiscal 2025, up 550.0% on the year before.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025
Revenue1,8002001,300
Growth on the year before—−88.9%+550.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Licenses $1.3M ▲ 550.0%
License Non Affiliate $1.3M ▲ 550.0%

These categories overlap or exclude eliminations, so shares aren't shown.

From Inhibrx Biosciences, Inc.'s 10-K filed March 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Inhibrx Biosciences, Inc. $1.3m 550.0% —
Dare Bioscience, Inc. $1.4m 4366.5% —
Longeveron Inc. $1.2m -42.7% 10.4%
Cartesian Therapeutics, Inc. $1.5m 44.0% -68.8%
Absci Corp $1.6m -62.3% -43.3%
Ovid Therapeutics Inc. $1.6m -76.2% 99.8%

Compare with peers

Head to head: DARE vs INBXINBX vs LGVNINBX vs RNAC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inhibrx Biosciences, Inc.